EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer

Zhenya Yang, Mengting Zhou, Fenglin Luo, Shiqi Feng, Yu Tan, Qiqian Wang, Zeneng Cheng, Ruirong Tan, Rui Li

Frontiers in Pharmacology · 09.12.2025 · 16

DOI: 10.3389/fphar.2025.1667500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.12.2025. Verfasst von Zhenya Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) progression involves complex interactions between tumor cells, immune evasion, and metabolic reprogramming. Cryptotanshinone (CTS), a bioactive diterpenoid from Salvia miltiorrhiza , has demonstrated anticancer potential, but its integrated effects on CRC remain unclear.

Methods

We employed both in vitro and in vivo models to evaluate the therapeutic effects and mechanism of CTS. Using MC38 cells and mouse-derived CRC organoids, we assessed its impact on proliferation and apoptosis through CCK-8, clonogenic, and Annexin V/PI assays. For vivo evaluation, a murine AOM/DSS-induced CRC model was established and administered CTS via intraperitoneal injection for 8 weeks. Comprehensive analyses included histopathology, immune profiling by flow cytometry, 16S rRNA sequencing of gut microbiota, and LC-MS-based metabolomics.

Results

CTS exerted potent anti-CRC effects, suppressing tumor cell proliferation and inducing apoptosis in vitro . In AOM/DSS-induced mice, CTS significantly inhibited tumor growth, ameliorated colon shortening and pathological damage, and reduced inflammation. Mechanistically, CTS alleviated T cell exhaustion, reversed metabolic dysregulation, and restored gut microbiota community structure.

Conclusion

CTS effectively suppresses CRC progression. Its efficacy is associated with the coordinated modulation of the tumor-immune-microbiome axis, involving direct cytotoxicity, reduced PD-1+ T cell levels, and restructuring of the gut microbial community. These results highlight CTS as a promising multi-faceted therapeutic candidate and provide a preclinical rationale for its further development.

Schlagwörter

Stichwörter der Autor:innen

colorectal cancer therapygut microbiotaimmune checkpointmetabolic reprogrammingnatural productstumor microenvironment

Autor:innen und Institutionen

  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
  • Translational Chinese Medicine Key Laboratory of Sichuan, Sichuan-Chongqing Joint Key Laboratory of Innovation of New Drugs of Traditional Chinese Medicine, Sichuan Institute for Translational Chinese Medicine, Sichuan…
  • School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic…

Zitieren

APA

Yang, Z., Zhou, M., Luo, F., Feng, S., Tan, Y., Wang, Q., Cheng, Z., Tan, R., & Li, R. (2025). Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1667500

Vancouver

Yang Z, Zhou M, Luo F, Feng S, Tan Y, Wang Q, et al. Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1667500

BibTeX
@article{Yang2025,
  author = {Yang, Zhenya and Zhou, Mengting and Luo, Fenglin and Feng, Shiqi and Tan, Yu and Wang, Qiqian and Cheng, Zeneng and Tan, Ruirong and Li, Rui},
  title = {Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1667500}
}
Kostenlos starten →